Friday 6 November 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue: +14.5%
EPS: −43.6%
Free cash flow: +28.9%
Total debt: +142.7%

Quarter to September 2026, against a year earlier

110.57 3.03 −2.67%

Follow ABT

Alert me

Market cap: $196.6B
P/E: 42.3×
Fwd P/E: 35.1×
Dividend yield: 2.22%
F-score: 5/9
Altman Z: 5.61
Beneish M: −2.50
Dividend safety: 62/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Abbott Laboratories (ABT) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Medical Devices	21,387	48.25%
Diagnostic Products	8,937	20.16%
Nutritional Products	8,451	19.06%
Established Pharmaceuticals	5,536	12.49%
Gross margin		56.42%
Operating margin		18.17%
Pre-tax margin		19.10%

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Medical Devices	21,387 48.25%	18,986 45.26%	16,887 42.10%	14,802 33.91%	14,485 33.63%	11,787 34.06%	12,239 38.36%	11,370 37.18%	10,325 37.70%	—	—	—	—	—	—	—	—
Diagnostic Products	8,937 20.16%	9,341 22.27%	9,988 24.90%	16,469 37.73%	15,526 36.04%	10,805 31.22%	7,713 24.18%	7,495 24.51%	5,616 20.50%	4,813 23.08%	4,646 22.77%	4,721 23.32%	4,545 23.12%	4,292 22.53%	4,126 19.27%	3,794 10.79%	3,578 11.63%
Nutritional Products	8,451 19.06%	8,413 20.05%	8,154 20.33%	7,459 17.09%	8,294 19.25%	7,647 22.10%	7,409 23.22%	7,229 23.64%	6,925 25.28%	6,899 33.08%	6,975 34.18%	6,953 34.34%	6,740 34.29%	6,461 33.92%	5,989 27.98%	5,532 15.73%	5,284 17.18%
Established Pharmaceuticals	5,536 12.49%	5,194 12.38%	5,066 12.63%	4,912 11.25%	4,718 10.95%	4,303 12.43%	4,486 14.06%	4,422 14.46%	4,287 15.65%	3,859 18.51%	3,720 18.23%	3,118 15.40%	2,862 14.56%	2,769 14.54%	5,355 25.02%	4,461 12.69%	2,941 9.56%
Other Segments	—	—	—	—	—	—	57 0.18%	62 0.20%	237 0.87%	2,386 11.44%	2,272 11.13%	2,469 12.19%	2,498 12.71%	2,457 12.90%	2,604 12.16%	—	—
Cardiovascular And Neuromodulation Products	—	—	—	—	—	—	—	—	—	2,896 13.89%	2,792 13.68%	2,986 14.75%	3,012 15.32%	3,071 16.12%	3,333 15.57%	3,194 9.08%	2,692 8.75%
Proprietary Pharmaceutical Products	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	15,389 43.76%	13,545 44.03%
Unallocated Amount to Segment [Member] (Deprecated 2013-01-31)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2,797 7.95%	2,725 8.86%
Reportable Segment [Member] (Deprecated 2013-01-31)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	32,370	28,040
Revenue	44,328	41,950	40,109	43,653	43,075	34,608	31,904	30,578	27,390	20,853	20,405	20,247	19,657	19,050	21,407	35,167	30,765

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Medical Devices	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Diagnostic Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Nutritional Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Established Pharmaceuticals	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Cardiovascular And Neuromodulation Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Reportable Segment [Member] (Deprecated 2013-01-31)	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Segments	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2010
United States	17,126 38.63%	16,323 38.91%	15,452 38.53%	18,142 41.56%	16,642 38.63%	13,022 37.63%	11,398 35.73%	10,839 35.45%	9,673 35.32%	6,486 31.10%	6,270 30.73%	6,123 30.24%	6,208 31.58%	6,242 32.77%	15,194 43.21%
All Other Countries	15,979 36.05%	14,786 35.25%	14,168 35.32%	15,010 34.38%	15,726 36.51%	12,823 37.05%	11,936 37.41%	11,215 36.68%	9,943 36.30%	7,961 38.18%	4,549 22.29%	5,324 26.30%	4,662 23.72%	4,224 22.17%	8,250 23.46%
Germany	2,759 6.22%	2,539 6.05%	2,345 5.85%	2,340 5.36%	2,572 5.97%	2,108 6.09%	1,751 5.49%	1,619 5.29%	1,366 4.99%	1,044 5.01%	1,004 4.92%	978 4.83%	963 4.90%	837 4.39%	1,846 5.25%
China	1,907 4.30%	2,113 5.04%	2,253 5.62%	2,133 4.89%	2,392 5.55%	1,965 5.68%	2,346 7.35%	2,311 7.56%	2,146 7.83%	1,728 8.29%	1,796 8.80%	1,321 6.52%	1,083 5.51%	859 4.51%	—
Switzerland	1,871 4.22%	1,747 4.16%	1,638 4.08%	1,336 3.06%	1,313 3.05%	1,140 3.29%	1,068 3.35%	1,005 3.29%	841 3.07%	766 3.67%	784 3.84%	707 3.49%	792 4.03%	693 3.64%	—
India	1,871 4.22%	1,817 4.33%	1,750 4.36%	1,649 3.78%	1,561 3.62%	1,323 3.82%	1,397 4.38%	1,333 4.36%	1,237 4.52%	1,114 5.34%	1,053 5.16%	1,009 4.98%	922 4.69%	919 4.82%	501 1.42%
Japan	1,475 3.33%	1,441 3.44%	1,513 3.77%	1,932 4.43%	1,695 3.93%	1,386 4.00%	1,435 4.50%	1,326 4.34%	1,255 4.58%	924 4.43%	895 4.39%	968 4.78%	1,042 5.30%	1,221 6.41%	2,025 5.76%
United Kingdom	1,340 3.02%	1,185 2.82%	991 2.47%	—	—	—	—	—	—	—	430 2.11%	447 2.21%	395 2.01%	396 2.08%	888 2.53%
Netherlands	—	—	—	1,111 2.55%	1,174 2.73%	—	—	930 3.04%	929 3.39%	830 3.98%	855 4.19%	788 3.89%	960 4.88%	1,107 5.81%	2,001 5.69%
California	—	—	—	—	—	841 2.43%	573 1.80%	—	—	—	428 2.10%	462 2.28%	493 2.51%	471 2.47%	1,036 2.95%
Russian Federation	—	—	—	—	—	—	—	—	—	—	483 2.37%	536 2.65%	525 2.67%	485 2.55%	—
Colombia	—	—	—	—	—	—	—	—	—	—	388 1.90%	283 1.40%	205 1.04%	—	—
Italy	—	—	—	—	—	—	—	—	—	—	383 1.88%	436 2.15%	457 2.32%	412 2.16%	1,144 3.25%
Brazil	—	—	—	—	—	—	—	—	—	—	381 1.87%	508 2.51%	470 2.39%	448 2.35%	—
France	—	—	—	—	—	—	—	—	—	—	375 1.84%	—	480 2.44%	453 2.38%	1,216 3.46%
Viet Nam	—	—	—	—	—	—	—	—	—	—	331 1.62%	357 1.76%	—	—	—
Spain	—	—	—	—	—	—	—	—	—	—	—	—	—	283 1.49%	1,066 3.03%
International	27,202	25,627	24,657	25,511	26,433	21,586	20,506	19,739	17,717	—	—	—	—	—	—
Revenue	44,328	41,950	40,109	43,653	43,075	34,608	31,904	30,578	27,390	20,853	20,405	20,247	19,657	19,050	35,167

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Comparable sales growth	Q3 FY2026	7.00%	—	—

	Q3 FY2026	Q2 FY2026	Q1 FY2026
Comparable sales growth	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡
	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.